Update on The Rapid Blood Ammonia Testing Instrument ​Thomas Veltman, Ph.D.President and CTOAza Technology, Inc.tv@azatechnology.com Aza Technology has made significant progress towards the commercialization of our point-of-care Ammonia Monitoring Device (AMD).  In our previous update, we informed readers that we

What causes high ammonia and glycine in MMA? New insight into disease mechanisms from mouse and human tissues and a possible new treatment. MMA produces unique protein modifications that contribute to disease Dr. Charles Venditti’s lab at the National Institutes

Point-of-Care Ammonia Monitoring from a Single Drop of Blood ​Thomas Veltman, Ph.D., Aza Technology, Inc.tv@azatechnology.com ​In an earlier article in this newsletter, I described my efforts, along with a team of other researchers, towards producing a point-of-care ammonia meter with

PA Study at the NIH Natural History, Physiology, Microbiome and Biochemistry Studies of Propionic Acidemia Dr. Chuck Venditti and Dr. Oleg Shchelochkov seek Propionic Acidemia patients for their study. Hi – We are happy to announce that the NIH has

MMA Study at the NIH The NIH has been recruiting MMA patients to their study since 2004.  Below are links that describes the study and how to sign up. Clinical Study Links: Clinical and Basic Investigations of Methylmalonic Acidemia (MMA)

A Novel Gene Medicine Approach for the Treatment of Rare Early Onset Diseases LogicBio Therapeutics, Cambridge, MA   The field of gene therapy has experienced a renaissance in recent years, having rebounded from the clinical setbacks of decades past.  The

A novel messenger RNA therapeutic approach for the treatment of methylmalonic and propionic acidemias Moderna Therapeutics, Cambridge, MA MMA produces unique protein modifications that contribute to disease Moderna Therapeutics is a seven-year old company focused exclusively on developing medicines and

Tell us about Moderna Kelly Lindert, MD, is the Head of Metabolic Rare Diseases Clinical Development at Moderna, a biotechnology company in Cambridge, Mass. that is working to develop messenger RNA (mRNA) therapeutics for a variety of areas, including rare

Tell us about LogicBio Fred Chereau is the president and CEO of LogicBio Therapeutics, a biotechnology company in Cambridge, Mass., that is advancing an investigational therapy for methylmalonic acidemia(MMA). We sat down with him to talk about his work. Tell